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T cell responses are tightly regulated to maintain 
immune homeostasis and limit damage to vital 
organs. T cells in the liver, in particular, are sub-
jected to potent tolerizing mechanisms. Although 
these mechanisms prevent overzealous responses 
causing tissue injury, they may be exploited by 
hepatotropic pathogens to subvert antiviral im-
munity (Protzer et al., 2012). There have been 
major recent advances in our understanding of 
the multiple co-inhibitory pathways driving T cell 
exhaustion in the liver and perpetuating persistent 
viral infections (Protzer et al., 2012). However, the 
potential for NK cells to regulate T cell immunity 
has not been defined in human viral infections.
NK cells can contribute to the containment 
of many infections by intracellular pathogens 
(Orange et al., 2002; Khakoo et al., 2004; 
Lodoen and Lanier, 2006; Alter et al., 2011), 
acting though cytolytic or noncytolytic effects on 
target cells or by promoting adaptive immunity 
(Vivier et al., 2008). Accumulating data high-
light the capacity of NK cells to also exert a 
negative regulatory effect on T cells (Su et al., 
2001) through inhibition of antigen presen-
tation (Andrews et al., 2010), production of IL-10 
(Lee et al., 2009), or direct killing of T cells. 
Several receptor–ligand interactions between NK 
cells and T cells have been found to be capable 
of leading to autologous lysis of activated T cells 
(Rabinovich et al., 2003; Cerboni et al., 2007; 
Lu et al., 2007; Soderquest et al., 2011). More 
recently, NK cells have been shown to limit 
T cell immunity in a mouse model of chronic 
viral infection (Waggoner et al., 2010; Lang 
et al., 2012; Waggoner et al., 2012).
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Antiviral T cell responses in hepatotropic viral infections such as hepatitis B virus (HBV) are 
profoundly diminished and prone to apoptotic deletion. In this study, we investigate 
whether the large population of activated NK cells in the human liver contributes to this 
process. We show that in vitro removal of NK cells augments circulating CD8+ T cell  
responses directed against HBV, but not against well-controlled viruses, in patients with 
chronic hepatitis B (CHB). We find that NK cells can rapidly eliminate HBV-specific T cells 
in a contact-dependent manner. CD8+ T cells in the liver microcirculation are visualized 
making intimate contact with NK cells, which are the main intrahepatic lymphocytes 
expressing TNF-related apoptosis-inducing ligand (TRAIL) in CHB. High-level expression of 
the TRAIL death receptor TRAIL-R2 is found to be a hallmark of T cells exposed to the 
milieu of the HBV-infected liver in patients with active disease. Up-regulation of TRAIL-R2 
renders T cells susceptible to caspase-8–mediated apoptosis, from which they can be par-
tially rescued by blockade of this death receptor pathway. Our findings demonstrate that 
NK cells can negatively regulate antiviral immunity in chronic HBV infection and illustrate 
a novel mechanism of T cell tolerance in the human liver.
© 2013 Peppa et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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were able to simultaneously compare the effect of NK depletion 
on HBV- and CMV-specific responses; those directed against an 
immunodominant CMV epitope showed a nonsignificant trend 
to decrease, contrasting with the increase in T cells directed 
against HBV in the same patients (Fig. 2 A). Similarly, EBV- and 
influenza-specific T cell responses in patients with CHB were 
not augmented upon the removal of NK cells (Fig. 2 B). In pa-
tients persistently infected with another hepatotropic virus, hep-
atitis C (Table S3), there was also no consistent increase in T cells 
able to recognize 2 immunodominant HLA-A2–restricted HCV 
epitopes upon NK cell depletion (Fig. 2 C). These data therefore 
point to differential NK cell regulation of T cells according to 
their antigen specificity.
NK cells limit HBV-specific CD8+ T cell responses  
in a contact-dependent manner by inducing apoptosis
Our initial findings suggested NK cells could be suppressing 
HBV-specific CD8+ T cells in culture or could be actively 
deleting them. To investigate the latter possibility, freshly puri-
fied NK cells were re-added at day 10, just 6 h before analysis 
of HBV-specific CD8+ T cell numbers. A diminished HBV-
specific CD8+ T cell response was observed irrespective of 
the timing of NK cell re-addition (representative example 
and summary data can be found in Fig. 3 A). The speed of this 
effect precluded a requirement for the inhibition of prolifera-
tive expansion of virus-specific CD8+ T cells in culture, instead 
indicating that these populations were amenable to rapid 
functional inactivation or deletion by NK cells.
To distinguish between these two possibilities, HBV-
specific CD8+ T cells were identified by HLA-A2/peptide 
multimer rather than IFN- staining after removal of NK cells 
at day 0 or 1 and re-addition of a physiological ratio of freshly 
isolated NK cells on day 0 or 10. Multimer-binding CD8+  
T cells were only increased if NK cells were removed at the be-
ginning of the culture (not on day 1), and were decreased again 
after re-addition of NK cells on day 0 or 10 (Fig. 3 B). These 
results indicated that NK cells were able to rapidly deplete the 
number of virus-specific CD8+ T cells surviving in culture.
The mechanism of action of NK cells on virus-specific 
T cell survival during short-term culture was further investigated 
by transwell experiments. A physiological ratio of NK cells was 
re-added at day 0 directly to the culture or to transwells separated 
from the T cells by a semipermeable membrane. When NK cells 
were not in contact with T cells, their survival was enhanced to a 
degree similar to that seen upon NK cell depletion (Fig. 3 C, top). 
The degree of pancaspase activation in HBV-specific T cells (in-
dicating apoptosis induction) was reduced when NK cells were 
depleted or not in contact with T cells, whereas re-addition of 
NK cells increased the amount of early (FLICA+7AAD) and 
late (FLICA+7AAD+) apoptotic events (Fig. 3, C and D, and not 
depicted). Thus, NK cell induction of T cell apoptosis required 
cell–cell contact.
Collectively, these results indicate that at least some of the 
impact of NK cells on HBV-specific T cells is mediated by a di-
rect effect on their survival that is contact-dependent and results 
in caspase activation.
In this study, we sought to investigate the impact of NK 
cells on antiviral T cell responses in the setting of persistent 
infection with a human hepatotropic virus. Activated NK 
cells are markedly enriched in the liver microcirculation, 
where we hypothesized they would come into prolonged, 
close contact with infiltrating T cells. Although NK cells in 
patients with chronic hepatitis B (CHB) infection have impaired 
noncytolytic antiviral function, we have previously shown 
that they maintain their cytotoxic potential and up-regulate 
the death ligand TRAIL, particularly in the intrahepatic com-
partment (Dunn et al., 2007; Peppa et al., 2010). HBV-specific 
CD8+ T cells, which are essential for viral control, are pro-
foundly depleted in these patients (Maini et al., 2000; Boni 
et al., 2007). Here, we demonstrate that hepatitis B virus–specific 
T cells up-regulate a death receptor for TRAIL and become 
susceptible to NK cell–mediated killing, thereby contributing 
to the failure of antiviral immunity in CHB.
RESULTS
Recovery of HBV-specific CD8+ T cells  
after depletion of NK cells
To investigate whether NK cells have the potential to regulate 
virus-specific CD8+ T cells, we initially determined the impact 
of total NK cell depletion on the magnitude of HBV-specific 
T cell responses. CD8+ T cell responses against a pool of peptides 
representing well-described HLA-A2–restricted HBV epitopes 
or overlapping peptides (15mers) spanning the core protein of 
HBV were identified by IFN- production after short-term cul-
ture. Fig. 1 A is a representative example of HBV responses from 
a patient with active CHB in the presence or absence of NK 
cells. Stimulation of whole PBMCs resulted in the expected low 
frequency of responses, in line with the well-established paucity 
of detectable HBV-specific T cells in CHB (Maini et al., 2000; 
Boni et al., 2007). Upon NK cell depletion, there was an en-
hancement of HBV-specific CD8+ T cells, which returned to 
baseline levels after re-addition of purified NK cells at a physio-
logical ratio at the start of culture. Individual responses and sum-
mary data are depicted in Fig. 1 (B and C), showing a significant 
recovery of HBV-specific CD8+ T cells upon NK cell depletion 
from patients with CHB. To exclude any potential contribution 
of other lymphocyte subsets, including NKT cells, depletion ex-
periments were also performed after flow-cytometric sorting of 
NK cells to 99% purity (Fig. 1 D). Removal of NK cells also 
promoted the expansion of a population of CD8+ T cells able to 
bind HLA-A2/HBV peptide multimers (Fig. 1 E). This implied 
that NK cells were influencing the number of HBV-specific 
CD8+ T cells surviving in culture, not just the function of pre-
existing populations.
Differential effects of NK cells  
according to T cell specificity
To explore whether NK cell depletion could similarly augment 
other virus-specific responses, we analyzed CD8+ T cells directed 
against immunodominant HLA-A2–restricted epitopes from cy-
tomegalovirus (CMV), Epstein–Barr virus (EBV), and influenza 
in our cohort of CHB patients. In 22 patients with CHB, we 
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Figure 1. Recovery of HBV-specific CD8+ T cells after depletion of NK cells. (A) Representative FACS plots from a CHB patient. HBV-specific CD8+ T cells 
were identified by intracellular cytokine staining for IFN- after 10-d stimulation with a pool of HBV peptides of PBMCs or PBMCs depleted of NK cells (NK). 
Where indicated, a physiological ratio of NK cells was re-added in the culture at day 0 before stimulation. (B) Individual responses of CHB patients (n = 27) and 
matched summary data (C). (D) NK cells were sorted to 99% purity by flow cytometry. Control PBMCs stained with the same antibodies were passed though the 
machine untouched. Summary bar graph of (n = 3) experiments. (E) HBV-specific CD8+ T cells were identified by MHC peptide multimer staining after short-term 
peptide stimulation in the absence or presence of NK cells or NK cell re-addition at day 0. Representative FACS plots from a CHB patient and summary data from 
(n = 9) CHB patients. Error bars represent the mean ± SEM. ND = not detected. ***, P < 0.001; **, P < 0.01.
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receptor pathway from the TNF superfamily that was able 
to induce apoptosis through caspase 8 (Sprick et al., 2000). 
We focused on the TRAIL pathway because we have pre-
viously found TRAIL to be up-regulated on NK cells dur-
ing episodes of HBV-related liver inflammation (Dunn 
et al., 2007; Peppa et al., 2010). We therefore investigated 
whether the dysregulated T cell response in patients with 
Increased TRAIL-R2 expression on T cells in CHB
Several ligand–receptor interactions could be responsible 
for mediating NK cell killing of T cells through caspase in-
duction. We noted that HBV-specific CD8+ T cells stained 
directly ex vivo had an increase in their expression of acti-
vated caspase 8 compared with CMV-specific or global CD8+ 
T cells (unpublished data). This indicated a death ligand 
Figure 2. Differential regulation by NK cells according to T cell specificity. (A) Representative FACS plots for CMV-specific responses from a CHB 
patient upon PBMC stimulation and in the absence of NK cells (NK) and summary bar graphs comparing CD8+ T cell responses upon HBV or CMV pep-
tide stimulation within the same (n = 22) CHB patients ± NK cell depletion. (B) Representative FACS plots for EBV and influenza virus–specific responses 
from a CHB patient upon PBMC stimulation and in the absence of NK cells (NK) and summary data for EBV (n = 6) and influenza (n = 7). (C) Example of 
HCV virus–specific CD8+ T cell identification by tetramer staining during short-term culture in the presence and absence of NK cells and summary bar 
graph from n = 8 HCV patients. Error bars represent the mean ± SEM. **, P < 0.01.
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Figure 3. NK cells limit the survival of CD8+ HBV-specific T cells in a contact-dependent manner by inducing apoptosis. (A) Representative FACS plots 
from a CHB patient. HBV-specific CD8+ T cells were identified by intracellular cytokine staining for IFN- after 10-d stimulation with a pool of HBV peptides upon NK 
cell depletion (NK) or re-addition of freshly purified NK cells (physiological ratio) at day 0 or 10. Summary data from (n = 4) CHB patients. (B) FACS plots from a CHB 
patient depicting HBV-specific CD8+ T cells identified by multimer staining, after depletion of NK cells at day 0, or from PBMC culture at 24 h (Day 1) and re-addition 
of freshly purified NK cells at a physiological ratio on day 0 or 10. Summary bar graphs of n = 5 experiments. (C, top) Representative FACS plots from a CHB patient. 
HBV-specific CD8+ T cells were identified by multimer staining after short-term peptide stimulation in the absence (NK) or presence of NK cells. NK cells, where  
indicated, were re-added at a physiological ratio directly in the culture or were plated into transwells to prevent contact. (bottom) The corresponding proportions of 
apoptotic virus-specific cells. The degree of pancaspase activation was determined by flow cytometry using the carboxyfluorescein-FLICA apoptosis detection kit.  
Histograms represent early apoptotic (FLICA+7AAD) and late apoptotic (FLICA+7AAD+) virus-specific CD8+ T cells. (D) Summary stacked bars of n = 3 experiments.
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infection (Dunn et al., 2007) and is known to have higher 
affinity for membrane-bound TRAIL (Schneider et al., 
1998; Ichikawa et al., 2001). We therefore compared the 
expression of TRAIL-R2 on global T cells in CHB and 
healthy controls directly ex vivo. Levels of TRAIL-R2 
were low on peripheral CD8+ T cells in CHB but were 
significantly elevated compared with the negligible levels 
CHB might become susceptible to TRAIL-mediated kill-
ing by up-regulation of TRAIL death receptors. TRAIL 
binding to the death receptors TRAIL-R1 and TRAIL-R2, 
which contain intracytoplasmic domains, triggers caspase 
activation and induction of apoptosis (Schneider et al., 1997; 
Kimberley and Screaton, 2004). TRAIL-R2 is up-regulated 
on the surface of hepatocytes during active flares of HBV 
Figure 4. Higher levels of TRAIL-R2 on T cells in patients with CHB. (A) Representative FACS plots and isotype control from a healthy individual and a 
CHB patient showing expression of TRAIL-R2 on global peripheral CD8+ T cells, and summary data from n = 18 healthy and n = 27 CHB patients. (B) FACS 
plots depicting identification of virus-specific CD8+ T cells ex vivo via multimer staining from a representative CHB patient, and gating strategy showing ex-
pression of TRAIL-R2 on virus-specific cells. A control multimer was used to help identify the virus-specific populations. (C) Paired data showing expression of 
TRAIL-R2 on HBV versus CMV virus-specific CD8+ T cells from (n = 9) CHB patients. (D) Representative FACS plot from an individual with resolved HBV infec-
tion, showing gating for HBV-specific CD8+ T cells and TRAIL-R2 expression. (E) Summary bar graphs of TRAIL-R2 expression on HBV-specific CD8+ T cells 
from seven individuals with resolved HBV infection and nine CHB individuals. Error bars represent the mean ± SEM. *, P < 0.05; **, P < 0.01.
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TRAIL-R2 expression was then compared on CD8+  
T cells directed against CMV or HBV within the same CHB 
patients, identified directly ex vivo by MHC/peptide multi-
mer staining (Fig. 4 B). A significantly higher proportion of 
seen in healthy controls (Fig. 4 A). No significant corre-
lation was observed between the levels of expression of 
TRAIL-R2 and any virological or clinical parameters in 
the periphery (unpublished data).
Figure 5. Intrahepatic CD8+ T cells in CHB patients have up-regulated expression of TRAIL-R2. (A) Representative example of immunostaining 
of paraffin-embedded liver tissue (derived from a CHB patient undergoing diagnostic biopsy) showing CD8+ T cells and TRAIL-R2 colocalization by immuno-
fluorescence. Bars, 20 µm. (B) Representative FACS plots from a CHB patient showing ex vivo expression of TRAIL-R2 on global peripheral and intrahepatic  
CD8+ T cells. (C) Ex vivo TRAIL-R2 expression on paired peripheral and intrahepatic global CD8+ T cells from (n = 21) patients with CHB. (D) Correlation  
of TRAIL-R2 expression on intrahepatic CD8+ T cells and HBV viral load. Spearman r = 0.4870, P value (two-tailed) = 0.02 (E) Comparison of TRAIL-R2  
expression on intrahepatic CD8+ T cells from 8 patients with nonviral hepatitis (control), 7 HCV-infected patients, and 21 CHB patients. (F) Co-staining  
for TRAIL-R2 and HLADR gated on intrahepatic global CD8+ T cells directly ex vivo from a CHB patient, a HCV patient, and a nonviral hepatitis control 
patient; and summary data from control (n = 5), HCV (n = 6), and CHB (n = 10) patients. ***, P < 0.001; **, P < 0.01; *, P < 0.05.
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Figure 6. TRAIL-R2 expression is a feature of CD8+ T cells encountering antigen in the HBV-infected liver. (A) Representative gating strategy 
identifying intrahepatic TRAIL-R2+ high (red), TRAIL-R2+ low (black), and TRAIL-R2 negative (gray) CD8+ T cells from a CHB patient. Histograms and bars 
depict the proportions of CD38 (n = 4), Annexin V (n = 3), PD1 (n = 6), and CD57 (n = 8) expressed by each subset directly ex vivo. (B) The maturation 
status of intrahepatic TRAIL-R2+ high (red), TRAIL-R2+ low (black), and TRAIL-R2 negative (gray) CD8+ T cells were analyzed by co-staining for CD27 and 
CD45RA. Representative FACS plot and summary bars of frequencies of expression of TRAIL-R2+ high (red), TRAIL-R2+ low (black), and TRAIL-R2 negative 
(gray) CD8+ T cells with naive, central memory (CM), effector memory (EM) and revertant (EMRA) phenotypes from n = 4 CHB patients. (C) Summary bar 
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To further explore the characteristics of global intrahe-
patic CD8+ T cells bearing TRAIL-R2, we compared the 
expression of a panel of phenotypic markers on TRAIL-R2 
high, low, and negative fractions (Fig. 6, A and B). TRAIL-R2 
expressing CD8+ T cells were enriched for the activation 
marker CD38 (in line with the co-staining with HLA-DR 
demonstrated in Fig. 5 F) and the apoptosis marker Annexin V, 
but not for the exhaustion marker PD-1 (Fig. 6 A). Cells 
expressing high levels of TRAIL-R2 were less likely to be 
found in the CD57+ and CD27-CD45RA+ subsets and were 
instead mainly of a central memory phenotype (Fig. 6, A and B). 
These data suggest that TRAIL-R2–expressing CD8+ T cells 
are activated, apoptotic responses rather than exhausted or 
senescent populations.
The large proportion of total intrahepatic CD8+ T cells 
bearing TRAIL-R2 in CHB led us to question whether its 
expression was restricted to HBV-specific T cells. In five 
HLA-A2+ individuals from whom sufficient liver-infiltrating 
lymphocytes could be obtained, responses directed against 
HBV or CMV were compared directly ex vivo by HLA-A2/
peptide multimer staining. The expression of TRAIL-R2 was 
higher on intrahepatic CMV-specific CD8+ T cells compared 
with the low levels seen on CD8+ T cells of this specificity in 
the periphery. However, TRAIL-R2 was further enriched on 
intrahepatic HBV-specific CD8+ T cells (Fig. 6 C). Upon rec-
ognition of their cognate antigen after overnight stimulation 
with HBV peptides, the majority of virus-specific CD8 from 
HBV-infected livers expressed TRAIL-R2 (Fig. 6 D). An up-
regulation of TRAIL-R2 was also observed after stimulation 
with CMV peptide on intrahepatic virus-specific CD8+  
T cells from HBV-infected patients (Fig. 6 D). In contrast, 
CMV-specific CD8+ T cells from control livers without hep-
atitis failed to express any TRAIL-R2 upon peptide stimula-
tion (Fig. 6 D). Thus, high TRAIL-R2 expression appeared to 
be a hallmark of T cells encountering their cognate antigen in 
the milieu of an HBV-infected liver.
TRAIL blocking partially recovers HBV-specific CD8+ T cells
We next sought functional evidence for the involvement of 
the TRAIL pathway in NK-cell mediated deletion of virus-
specific T cells. To do this, we examined the impact of TRAIL 
blockade at the time of peptide stimulation of PBMCs on 
HBV-specific CD8+ T cell responses in vitro. TRAIL block-
ing experiments were performed with a TRAIL-R2 Fc, com-
pared with a control IgG1 Fc to exclude a nonspecific effect 
(Fig. 7 A). Fig. 7 A presents representative FACS plots from a 
CHB patient and summary data from nine CHB patients 
HBV-specific CD8+ T cells expressed TRAIL-R2 compared 
with CMV-specific responses (Fig. 4 C), in line with their 
differential susceptibility to NK cell modulation. No up-
regulation of TRAIL-R2 was observed on HBV-specific CD8+ 
T cells obtained from individuals who had previously resolved 
HBV infection (Fig. 4, D and E). These data indicated that 
TRAIL-R2 was preferentially induced on HBV-specific 
CD8+ T cells encountering their cognate antigen.
Further up-regulation of TRAIL-R2  
on intrahepatic CD8+ T cells in CHB
Because the TRAIL-R2 death receptor was up-regulated in 
CHB, particularly on HBV-specific T cells, we hypothesized 
that its expression might be further enriched in the liver, the 
site of HBV replication. To determine whether TRAIL-R2 
was expressed on CD8+ T cells infiltrating the liver, we ini-
tially examined paraffin-embedded sections of HBV-infected 
livers by immunofluorescence. Using this approach, we noted 
clear co-staining of CD8+ T cells in the liver with TRAIL-R2 
(Fig. 5 A). We expanded on these data by extracting liver-
infiltrating lymphocytes from surplus liver biopsy tissue, allow-
ing flow cytometric comparison of TRAIL-R2 expression on 
paired circulating and intrahepatic CD8+ T cell samples. In 
19 out of 21 patients with CHB, the expression of TRAIL-
R2 on CD8+ T cells was further increased in the liver com-
pared with the peripheral compartment (Fig. 5 B, C). There 
was considerable variability in TRAIL-R2 expression levels 
on intrahepatic CD8+ T cells (Fig. 5 C), and this was found to 
correlate positively with HBV viral load (Fig. 5 D). These data 
suggested that the liver environment and HBV may both be 
factors driving up-regulation of this death receptor. To address 
this, we obtained surplus liver tissue from seven patients with 
HCV and eight individuals without viral hepatitis. Liver- 
infiltrating CD8+ T cells from controls without viral hepatitis 
expressed more TRAIL-R2 than peripheral CD8+ T cells 
from healthy donors, but much less than those from HBV-
infected livers (Fig. 5 E). CD8+ T cells extracted from HCV-
infected livers showed a level of TRAIL-R2 expression that was 
intermediate between control and HBV-infected livers (Fig. 5 E). 
Levels of TRAIL-R2 were lower on CD8+ T cells from HCV-
infected as opposed to HBV-infected livers, despite the for-
mer group tending to be more inflamed (based on ALT levels; 
Tables S1 and S2). Levels of TRAIL-R2 were not simply a re-
flection of the degree of T cell activation; significantly more 
TRAIL-R2 was coexpressed by the HLA-DR+ (activated) 
fraction of CD8+ T cells extracted from HBV-infected livers 
compared with HCV or control livers (Fig. 5 F).
graphs comparing expression of TRAIL-R2 on global intrahepatic CD8+ T cells, CMV-specific and HBV-specific CD8+ T cells. Virus-specific CD8+ T cells were 
identified directly ex vivo by multimer staining in (n = 5) HLA-A2+ CHB patients with available liver biopsies. (D) Representative examples of the gating 
strategy from a control patient with no evidence of viral hepatitis (control liver) and a CHB patient (HBV liver) showing expression of TRAIL-R2  
on intrahepatic global CD8+ T cells and virus-specific CD8+ T cells identified via IFN- staining after overnight stimulation with CMV peptide and HBV 
overlapping peptides (OLP), respectively. Summary bar graphs comparing expression of TRAIL-R2 on CMV-specific CD8+ T cells from control livers (n = 5) 
versus CMV and HBV-specific CD8+ T cells from (n = 5) CHB patients. Bars represent the mean ± SEM. *, P < 0.05.
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PBMCs depleted of NK cells did not show any further in-
crease in the responses rescued above that observed upon NK 
depletion alone (Fig. 7 A).
No significant recovery of CMV-specific CD8+ T cells 
from the same patients with CHB was observed upon TRAIL 
blockade (Fig. 7 B), in keeping with the low levels of TRAIL-
R2 expressed on these cells in the circulation and the lack of 
their reconstitution upon NK cell depletion. Further support 
for the preferential deletion of a selective subset of TRAIL-
R2-bearing T cells by NK cells came from the finding that 
during short-term culture, which shows enhanced responses 
upon TRAIL blockade. However, the effect of TRAIL block-
ade was less striking than that of NK cell depletion in the 
same patients (Fig. 7 A), suggesting that NK cells were using 
additional pathways for deleting T cells. Although T cells can 
express TRAIL in some circumstances (Mirandola et al., 2004; 
Janssen et al., 2005), in our cohort, TRAIL expression was 
confined to NK cells (unpublished data), and we could there-
fore assume that TRAIL blockade of PBMCs was acting on 
NK cells. In support of this approach, TRAIL blocking of 
Figure 7. Partial recovery HBV-specific CD8+ T cells to TRAIL blockade. (A) Representative FACS plots from a CHB patient after short-term peptide 
stimulation of PBMCs in thepresence or absence of NK cells and in the presence of TRAIL-R2/Fc blocking or IgG1-Fc control. Plotted are summary paired 
data from (n = 9) CHB patients. (B) Representative FACS plot and summary data from n = 6 CHB patients showing the effect of TRAIL-R2 Fc addition at 
the time of PMBC stimulation with CMV peptide during short-term culture. (C) Representative example from a CHB patient demonstrating the expression 
of TRAIL-R2 on global CD8+ T cells in the presence or absence (NK) of NK cells after short-term culture with HBV peptides and summary data from (n = 19) 
CHB patients. Bars represent the mean ± SEM ***, P < 0.001; **, P < 0.01; *, P < 0.05.
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To test whether the T cells infiltrating HBV-infected liv-
ers were subject to death receptor-mediated apoptosis, we 
stained them for caspase 8, which is activated by these path-
ways from the TNF superfamily (Sprick et al., 2000). Caspase 
8 was detectable in a proportion of CD8+ T cells isolated 
from HBV-infected liver biopsies; its expression was enriched 
in the expanded population of intrahepatic CD8+ T cells 
expressing TRAIL-R2 on their surface (Fig. 8 B), in line with 
their enhanced expression of Annexin V (Fig. 6 A). These 
findings support the capacity of TRAIL-R2 to deliver an 
apoptotic signal to the large proportion of intrahepatic CD8+ 
T cells on which it is expressed in CHB.
To assess whether TRAIL blocking was capable of restoring 
virus-specific T cell responses in the liver, we examined paired 
samples from nine HLA-A2 CHB patients from whom suf-
ficient liver biopsy tissue was available for functional experi-
ments. Overlapping peptides (15mers) spanning the core 
protein of HBV were used for overnight stimulation, and 
both peripheral and intrahepatic virus-specific T cell re-
sponses were assessed for IFN- production in the presence 
or absence of TRAIL blocking. Despite the fact that many 
of these cells were already poised to die, with activation 
of intracellular caspases, intrahepatic HBV-specific CD8+  
T cell responses could be augmented after just overnight 
TRAIL blockade in four out of nine patients (Fig. 8 C). In 
contrast, the expansion of detectable HBV-specific T cell 
responses from PBMCs could only be achieved after 10 d 
the percentage of global CD8+ T cells expressing TRAIL-R2 
was increased after depletion of NK cells from HBV peptide-
stimulated PBMC cultures (Fig. 7 C).
Overnight rescue of intrahepatic HBV-specific  
T cells by TRAIL blockade
NK cells constitute up to 40% of the lymphocytic infiltrate 
within the liver, the site of HBV replication. We have previ-
ously shown that intrahepatic NK cells in patients with HBV-
related inflammation are highly activated and express increased 
levels of TRAIL compared with circulating NK cells, whereas 
intrahepatic CD3+ T cells express little TRAIL (Dunn et al., 
2007). The extensive sinusoidal network in the liver forms a 
unique vascular bed with a narrow lumen and sluggish blood 
flow. We postulated that this would facilitate close associations 
between NK cells and T cells as they infiltrated the liver. To 
investigate this, we performed staining of paraffin-embedded 
liver sections from patients with CHB by immunohistochem-
istry. Using this approach we were able to visualize intimate 
contact between NK cells and T cells in the HBV-infected 
liver sinusoids, as exemplified in Fig. 8 A. This supported 
the concept that the intrahepatic predominance of TRAIL-
expressing NK cells, in conjunction with the unique archi-
tecture of the liver encouraging close contact between 
lymphocyte subsets, would promote the deletion of TRAIL-
R2–bearing T cells.
Figure 8. Overnight recovery of intrahe-
patic HBV-specific T cells by TRAIL block-
ade. (A) Examples of NK cells (NKp46 in blue) 
in intimate contact with CD3+ T cells (red) in 
the sinusoidal spaces of a representative HBV-
infected liver. Immunohistochemistry was 
performed on paraffin-embedded HBV tissue. 
Bars 20 µm. (B) Representative FACS plot from 
a CHB patient and gating strategy showing 
expression of caspase 8 in intrahepatic TRAIL-
R2+ CD8+ T cells ex vivo and summary bar 
graphs comparing expression of caspase 8 in 
global CD8+ T cells versus TRAIL-R2+ CD8+  
T cells (n = 5). Only live events were analyzed. 
(C) Representative FACS plots showing re-
sponse to TRAIL blockade after overnight 
incubation of intrahepatic cells with overlap-
ping (OLP) HBV peptides and individual intra-
hepatic responses from nine CHB patients 
with available liver tissue.
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over-ridden according to the type of infection. This concept is 
supported by population genetic studies that have demonstrated 
that KIR haplotypes are under balancing selection and can be 
associated with resistance to infection (Khakoo et al., 2004; Alter 
et al., 2011) but also autoimmunity and immunopathology 
(Parham, 2005; Kulkarni et al., 2008). Although speculative, it is 
possible that reported associations between KIR haplotypes 
and outcome of infections with HIV, HCV and HTLV-1 
(Khakoo et al., 2004; Alter et al., 2011; Seich Al Basatena et al., 
2011) may in part be determined by differential NK cell regula-
tion of antiviral T cell responses. In CHB, the protective effect of 
MHC class I molecule expression may be insufficient for self 
tolerance in the face of selective up-regulation of receptors/ 
ligands superseding control of self-killing.
Although we have delineated a role for the TRAIL path-
way, our data imply that additional receptor–ligand interac-
tions could contribute to driving NK cell lysis of T cells in 
CHB. The capacity of NK cells to lyse LCMV-specific CD8+ 
T cells has been shown to be regulated by 2B4 (Waggoner 
et al., 2010) or NKG2D (Lang et al., 2012); the impact of HBV 
infection on relevant pathways regulating NK cell cytotoxic-
ity merits investigation. The recent studies in LCMV show 
that NK cells can regulate CD8+ T cell responses not only by 
direct killing (Waggoner et al., 2010; Lang et al., 2012), as 
demonstrated in our experiments, but also via elimination 
of CD4+ T cell responses (Waggoner et al., 2012). This find-
ing may also be pertinent to the liver, where CD4+ T cell 
numbers are already low and priming is defective (Wuensch 
et al., 2010).
The contrasting effects of NK cell removal on HBV-
specific T cells and responses to unrelated viruses (CMV, 
EBV, and influenza) within the same patients pointed to-
ward differential NK cell–T cell receptor–ligand interac-
tions depending on their antigenic exposure. In line with 
this, TRAIL-R2 was found to be substantially higher on the 
surface of HBV-specific cells compared with CMV-specific 
cells, suggesting that the features of HBV-specific CD8+  
T cells that target them for NK cell–mediated deletion are not 
shared by T cells of all virus specificities. The expression of 
TRAIL-R2 was increased globally on activated, apoptotic 
intrahepatic CD8+ T cells, although more so in CHB than 
HCV-infected or other control liver samples. It is conceiv-
able that antigen presentation in the tolerogenic liver 
environment is able to impose a TRAIL-R2-expressing 
phenotype on T cells, as described for the pro-apoptotic 
molecule Bim (Holz et al., 2008). The hepatic cytokine mi-
lieu (Dunn et al., 2007) and HBV antigens (Janssen et al., 
2003) can up-regulate TRAIL-R2 expression on hepato-
cytes, and could likewise affect its expression on intrahepatic 
T cells. In addition, reactive oxygen species (ROS) have 
been shown to regulate T cell apoptosis (Hildeman et al., 
1999) and influence the expression of TRAIL receptors 
(Kwon et al., 2008) and may represent an important mecha-
nism in the liver.
Although healthy T cells are normally protected against 
the apoptotic effects of soluble TRAIL (Mirandola et al., 2004), 
rather than overnight TRAIL blockade (unpublished data). 
These results underscore the susceptibility of the enriched popu-
lation of HBV-specific T cells in the liver compartment to NK 
cell TRAIL-mediated deletion.
DISCUSSION
Persistent viral infection with HBV is associated with several 
T cell–intrinsic and –extrinsic defects, culminating in pro-
found depletion of the HBV-specific CD8+ T cell responses 
that constitute a critical component of antiviral defense (Boni 
et al., 2007; Lopes et al., 2008; Protzer et al., 2012). In this 
study, we addressed the role of NK cells, one of the main 
effectors of the innate immune response, in HBV-specific 
T cell modulation. Our results demonstrate that NK cells can 
limit virus-specific T cell responses, contributing to the apop-
totic predilection of these cells. NK cells from patients with 
CHB can mediate these effects without prior activation and 
at physiological ratios. NK cell–mediated regulation of T cell 
responses was found to be partly mediated through TRAIL. 
We have previously found TRAIL to be up-regulated on NK 
cells in flares of HBV-related liver inflammation and enriched 
in the intrahepatic compartment (Dunn et al., 2007). Here, 
we show that HBV-specific CD8+ T cells, particularly those 
infiltrating the liver, up-regulate the TRAIL-R2 death- 
inducing receptor. Therefore, NK cell–mediated deletion of 
virus-specific T cells via TRAIL may perpetuate viral persis-
tence and immunopathology, especially within the inflamma-
tory milieu of the intrahepatic compartment.
There is accumulating evidence suggesting that NK 
cells have an important immunoregulatory role (Zingoni 
et al., 2004; Martín-Fontecha et al., 2004; Morandi et al., 
2006; Andrews et al., 2010), in addition to a direct antiviral 
function in the setting of the early response to infection 
(Vivier et al., 2008). Our data are the first to reveal a path-
way for direct NK cell regulation of T cells in a human 
persistent viral infection. They are supported by recent 
studies highlighting a detrimental role of NK cells on the 
antiviral response in a murine model of persistent viral in-
fection (Waggoner et al., 2010, 2012; Lang et al., 2012). 
Activated NK cells have been described to target activated 
T cells in a cytolytic manner, resulting in a significant loss 
of lymphocytic choriomeningitis virus (LCMV)–specific 
CD8+ T effector cells, which leads to impaired virus control 
and altered immunopathology (Waggoner et al., 2010; Lang 
et al., 2012). A follow-up study further highlighted a role 
for NK cells as rheostats, regulating CD4+ T cell–mediated 
support of CD8+ T cells, and thereby controlling LCMV patho-
genesis and persistence (Waggoner et al., 2012). Thus, de-
pending on the context of infection and viral kinetics, 
NK cells may dictate viral clearance or immunopathology.
NK cell activation is the result of the balance of signals 
from a complex array of activatory and inhibitory receptors, 
combined with the cytokine milieu. The fact that NK cells 
can potentially have either a beneficial or deleterious effect 
on autologous T cells implies that the protective effect of 
MHC in maintaining self-tolerance may be supported or 
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MATERIALS AND METHODS
Patients and healthy controls. Patients were recruited from Mortimer 
Market Clinic (London), the Royal Free Hospital (London), and the Royal 
London Hospital. Full ethical approval was obtained and each patient gave 
written informed consent. All CHB patients were anti-HCV and anti-HIV 
antibody negative and treatment naive. Seven patients who had resolved 
previous HBV infection and 18 age-matched healthy volunteers donated 
blood for the study. Patient characteristics are included in Table I. Liver 
samples were obtained from 21 HLAA2 patients with CHB and paired pe-
ripheral and intrahepatic samples. Surplus liver tissue was available from five 
HLAA2+ and four HLA-A2 patients with CHB undergoing diagnostic 
liver biopsies (Table S1). Characteristics of patients with HCV and controls 
without viral hepatitis from whom liver tissue was available are outlined in 
Table S2. Characteristics of HCV patients from whom only PBMCs were 
used shown in Table S3.
PBMC and intrahepatic lymphocyte isolation. PBMCs were isolated 
by gradient centrifugation on Ficoll-Hypaque and frozen or immediately 
studied as described later. Sera were collected and frozen for later use. Intra-
hepatic lymphocytes were isolated as previously described (Peppa et al., 
2010) In brief, liver tissue was suspended in RPMI-1640 (Sigma-Aldrich) 
and macerated with a plunger from a 25-ml syringe and a scalpel in a Petri 
dish. The cell suspension was then passed several times through a 70-mm cell 
strainer (BD), washed three times, and resuspended in RPMI complete me-
dium with 10% fetal bovine serum for counting. Lymphocytes were identi-
fied under a high magnification by their size, shape, and granularity.
Purification of NK cells. Freshly purified NK cells from PBMCs of CHB 
patients were isolated (>96% purity and viability; NK isolation kit; Miltenyi 
Biotec) as per the manufacturer’s instructions. NK cells were depleted by 
CD56 MACS microbeads (Miltenyi Biotec); TRAIL expression on NK 
cell–enriched fractions was confirmed by flow cytometry. Where indicated, 
separated NK cells were plated into transwells (1 µm pore size; Polycarbon-
ated Membrane; Corning Costar). FACS of NK cells (99% purities) was per-
formed on the basis of CD56 expression (CD56+CD3) by FACSAria (BD). 
Control PBMCs stained with the same antibodies were passed though the 
machine untouched.
Flow cytometric analysis. For phenotypic analysis, PBMCs isolated from 
HBV patients and healthy donors were washed in PBS, and surface stained 
at 4°C for 20 min with saturating concentrations of monoclonal anti-CD3 
PE-Cy7, CD8 Alexa Fluor 700, HLADR V500, CD19 V450, CD4 APC-
Cy7 (eBioscience), CD56-TEXAS Red (Beckman Coulter), and TRAIL-
R2 (R&D Systems) in the presence of fixable live/dead stain (Invitrogen). 
Where stated, the degree of activated caspase 8 and activated pancaspases 
were determined using the FAM-LETD-FMK or the carboxyfluorescein-
(FAM-VAD-FMK) FLICA kit (Serotec) according to the manufacturer’s in-
structions. For further phenotypic analysis of intrahepatic CD8+ T cells, the 
following antibodies or isotype-matched controls were used: CD38-FITC 
(BD), CD45RA V450 (eBioscience), CD27 V500 (BD), PD1-PERCP 
(eBioscience), CD57-APC (BD) in the presence of fixable live/dead stain 
(Invitrogen). Where indicated, the viability of CD8+ T cells was further 
assessed by staining for Annexin V (BioLegend) according to the manu-
facturer’s protocol in the presence of 7AAD viability staining solution. 
several studies suggest that viral infections can render 
lymphoid cells susceptible to TRAIL-mediated cytotoxic-
ity (Katsikis et al., 1997; Jeremias et al., 1998; Miura et al., 
2001). We find that cells expressing high levels of TRAIL-
R2 in the liver are poised to die, with elevated levels of in-
tracellular caspase 8. We would therefore anticipate that 
receptor blockade would be more effective in vivo than in 
vitro, allowing for rescue of newly generated antiviral 
CD8+ T cells before they are driven to their apoptotic fate. 
We have previously demonstrated that pretreatment of 
PBMCs from HBV patients with a pancaspase inhibitor 
before peptide stimulation can rescue HBV-specific CD8+ 
T cells that have up-regulated Bim (Lopes et al., 2008). 
TRAIL signaling can also lead to Bim up-reglation (Han 
et al., 2006; Cummins and Badley, 2009) and it is likely that 
the two pathways converge (Bouillet and O’Reilly, 2009), 
increasing the apoptotic propensity of virus-specific cells. 
TRAIL expression on NK cells is increased during disease 
flares (Dunn et al., 2007), which would be predicted to result in 
an accelerated deletion of T cells expressing TRAIL receptors. 
Ongoing high-level expression of TRAIL-R2–bearing T cells 
in the HBV-infected liver is consistent with the constant 
renewal of antigen-primed T cells in persistent viral infec-
tions (Vezys et al., 2006) and with our phenotypic character-
ization of these populations.
In the inflamed HBV-infected liver, the prominence 
of activated NK cells bearing high levels of TRAIL may 
have the dual effect of both contributing to death of he-
patocytes (Dunn et al., 2007) and of promoting apoptosis 
of T cells with up-regulated TRAIL receptors. However 
it is important to note that TRAIL-bearing NK cells have 
also been suggested to protect against tumors in the murine 
liver (Takeda et al., 2001) and to counteract liver fibrosis 
in chronic hepatitis C (Glässner et al., 2012). With these 
considerations in mind, the timing of TRAIL blockade in 
the liver would need to be carefully considered. As a short-
term adjuvant to the immunotherapy of CHB, TRAIL block-
ade could promote antiviral responses while minimizing 
liver inflammation.
In summary, we provide evidence of a novel pathway 
whereby activated NK cells may excessively down-modulate 
the antiviral immune response in CHB. NK cell–mediated 
deletion of T cells may represent an important homeostatic 
control mechanism to prevent exuberant T cell responses in 
the liver that has been hijacked by HBV to assist it in its on-
going battle to evade immune control.
Table 1. Characteristics of patients from whom PBMCs alone were available
Age in years 
median (range)
Sex (female:male) HBeAg+ HBV DNA IU/ml 
median (range)
ALT IU/L: median 
(range)
CHB patients (n = 27) 34 (23-51) 4:23 3/27 1,500 (36–7.3 × 107) 38 (17–378)
Resolved HBV (n = 7) 39 (29-69) 1:6 NA NA NA
Healthy controls (n = 18) 32 (21-49) 6:12 NA NA NA
NA, not applicable.
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Immunohistochemistry and immunofluorescence. Sections of archival 
paraffin-embedded HBV tissues were dewaxed and rehydrated, and epitope 
retrieval was performed as previously described (Dunn et al., 2007). All washes 
for immunostaining techniques and dilution of antibodies were done with 
EnVision FLEX wash buffer (Dako). After 2 min in Harris hematoxylin 
to block autofluorescence, immunostaining was performed on a Shandon 
Sequenza. After a 10-min endogenous protein block in 2% Casein solution 
(Vector), primary antibodies mouse anti-CD8 (Vector) at 1/50 dilution and 
polyclonal rabbit anti-DR5 (Abcam) at 1/100 were applied for 1 h. Visualiza-
tion was performed with anti–mouse DyLight 488 and anti–rabbit DyLight 
594 (Vector) at 1/200 dilution for 15 min. Sections were mounted with 
VECTASHIELD, with DAPI (Vector), and captured on a Zeiss Axiovision mi-
croscope with 1,000× magnification. Immunohistochemistry was performed 
on a Dako autostainer. After a 10-min peroxidase block (Dako), a 10-min en-
dogenous protein block in 2% Casein solution was applied. Sections were in-
cubated with mouse anti-CD3 (Dako) at 1/100 dilution for 30 min, visualized 
with mouse ImmPRESS (Vector), 30 min and ImmPACT NovaRED (Vector) 
for 5 min. After a water wash, 2% Casein solution was reapplied. Sections were 
then incubated in goat polyclonal anti-NKp46 (R&D Systems) at 1/100 dilu-
tion for 1 h, followed by biotinylated anti–goat secondary (Vector) and strept-
ABC alkaline phosphatase (Vector), as per manufacturer’s recommendations. 
Visualization was completed with Vector blue for 20 min. After counterstaining 
with Mayer’s hematoxylin (Leica), slides were rapidly dehydrated, cleared, and 
mounted in VectaMount (Vector Systems). Images were captured on a Leica 
DM with Nikon Coolpix camera at 1,260× magnification.
Statistical analysis. Statistical significance was performed between paired 
samples using the Wilcoxon signed rank test and between HBV patients and 
healthy controls using the Mann-Whitney U test. The nonparametric Spear-
man test was used for correlation analysis. P < 0.05 was considered to be sig-
nificant for all tests.
Online supplemental material. Tables S1–S3 detail clinical characteris-
tics of patients from whom liver biopsies or HCV-specific responses were 
acquired. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20121172/DC1.
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